Yahoo Web Search

Search results

1. • Factor Bioscience Successfully Defends Three U.S. Patents Covering Foundational Methods for...

     KOLR - KSFX Ozarks· 2 days ago

     -Patented methods relate to multiple allogeneic CAR T-cell therapies under clinical development for the treatment of B-cell lymphoma, chronic lymphocytic ...

2. • 

     GeoVax to Present at BIO International Convention 2024

     NewMediaWire via Yahoo Finance· 1 day ago

     Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and...

3. • Small Business - Salisbury Post | Salisbury Post

     The Salisbury Post· 7 days ago

     ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates PR Newswire SUZHOU, China and ROCKVILLE, Md., May 23, 2024 SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma

4. • 

     Nurix Therapeutics enhances leadership team By Investing.com

     Investing.com· 2 days ago

     Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in cancer and...

5. • 

     Cold agglutinin disease: Causes, symptoms, and treatments

     Medical News Today· 16 hours ago

     Cold agglutinin disease is a condition that causes low red blood cell (RBC) counts. Cold agglutinin...

6. • Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

     ETF DAILY NEWS· 4 days ago

     StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report published on Sunday. The firm issued a hold rating on the biotechnology company’s ...

7. • 

     Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks

     TipRanks via Yahoo Finance· 1 day ago

     There are few market signals that are clearer than those given by insiders’ stock purchases. To...

8. • 

     7 Large-Cap Stocks That Can Jump 50% By 2025

     InvestorPlace· 1 day ago

     Stock size is classified by market capitalization – current share price x number of shares outstanding – with large cap shares being above $10 billion....

9. • Antengene To Present One Oral and Four Abstracts at ASCO 2024

     FOX 23 News Albany· 7 days ago

     Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class ...

10. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

      Roanoke-Chowan News-Herald· 6 days ago

      - Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - EO2463 rapidly expands memory CD8+ T cells specific